Evidence map›Paper›PMID 28428226›Full record

ArticleMolecular pharmacology2017

Rapid Throughput Analysis of GABA

Atefeh Mousavi Nik, Brandon Pressly, Vikrant Singh, Shane Antrobus, Susan Hulsizer, Michael A Rogawski, Heike Wulff, Isaac N Pessah

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Atefeh Mousavi NikDepartment of Molecular Biosciences, School of Veterinary Medicine (A.M.N., S.A., S.H., I.N.P.), and Department of Pharmacology (B.P., V.S., M.A.R., H.W.), School of Medicine, University of California Davis, Davis, California; Department of Neurology, School of Medicine, University of California Davis, Sacramento, California (M.A.R.); and The Medical Investigation of Neurodevelopmental Disorders Institute, Sacramento, California (I.N.P.).
Brandon PresslyDepartment of Molecular Biosciences, School of Veterinary Medicine (A.M.N., S.A., S.H., I.N.P.), and Department of Pharmacology (B.P., V.S., M.A.R., H.W.), School of Medicine, University of California Davis, Davis, California; Department of Neurology, School of Medicine, University of California Davis, Sacramento, California (M.A.R.); and The Medical Investigation of Neurodevelopmental Disorders Institute, Sacramento, California (I.N.P.).
Vikrant SinghDepartment of Molecular Biosciences, School of Veterinary Medicine (A.M.N., S.A., S.H., I.N.P.), and Department of Pharmacology (B.P., V.S., M.A.R., H.W.), School of Medicine, University of California Davis, Davis, California; Department of Neurology, School of Medicine, University of California Davis, Sacramento, California (M.A.R.); and The Medical Investigation of Neurodevelopmental Disorders Institute, Sacramento, California (I.N.P.).
Shane AntrobusDepartment of Molecular Biosciences, School of Veterinary Medicine (A.M.N., S.A., S.H., I.N.P.), and Department of Pharmacology (B.P., V.S., M.A.R., H.W.), School of Medicine, University of California Davis, Davis, California; Department of Neurology, School of Medicine, University of California Davis, Sacramento, California (M.A.R.); and The Medical Investigation of Neurodevelopmental Disorders Institute, Sacramento, California (I.N.P.).
Susan HulsizerDepartment of Molecular Biosciences, School of Veterinary Medicine (A.M.N., S.A., S.H., I.N.P.), and Department of Pharmacology (B.P., V.S., M.A.R., H.W.), School of Medicine, University of California Davis, Davis, California; Department of Neurology, School of Medicine, University of California Davis, Sacramento, California (M.A.R.); and The Medical Investigation of Neurodevelopmental Disorders Institute, Sacramento, California (I.N.P.).
Michael A RogawskiDepartment of Molecular Biosciences, School of Veterinary Medicine (A.M.N., S.A., S.H., I.N.P.), and Department of Pharmacology (B.P., V.S., M.A.R., H.W.), School of Medicine, University of California Davis, Davis, California; Department of Neurology, School of Medicine, University of California Davis, Sacramento, California (M.A.R.); and The Medical Investigation of Neurodevelopmental Disorders Institute, Sacramento, California (I.N.P.).
Heike WulffDepartment of Molecular Biosciences, School of Veterinary Medicine (A.M.N., S.A., S.H., I.N.P.), and Department of Pharmacology (B.P., V.S., M.A.R., H.W.), School of Medicine, University of California Davis, Davis, California; Department of Neurology, School of Medicine, University of California Davis, Sacramento, California (M.A.R.); and The Medical Investigation of Neurodevelopmental Disorders Institute, Sacramento, California (I.N.P.).
Isaac N PessahDepartment of Molecular Biosciences, School of Veterinary Medicine (A.M.N., S.A., S.H., I.N.P.), and Department of Pharmacology (B.P., V.S., M.A.R., H.W.), School of Medicine, University of California Davis, Davis, California; Department of Neurology, School of Medicine, University of California Davis, Sacramento, California (M.A.R.); and The Medical Investigation of Neurodevelopmental Disorders Institute, Sacramento, California (I.N.P.) inpessah@ucdavis.edu.
NeuroDevelopment Center · USUniversity of California Davis Medical Center · USUniversity of California, Davis · US

Funding

Training and Education CoreU54NS079202 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ROGAWSKI, MICHAEL A. · 2012 to 2021
$35.7M
Rodent Behavior CoreU54HD079125 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SIMON, TONY J · 2013 to 2019
$8.5M
Predoctoral Training in Pharmacological SciencesT32GM099608 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HELL, JOHANNES W · 2012 to 2021
$2.2M
NICHD NIH HHS U54 HD079125NIGMS NIH HHS T32 GM099608NINDS NIH HHS U54 NS079202
6 · The paper itself

Abstract

Fluorometric imaging plate reader membrane potential dye (FMP-Red-Dye) is a proprietary tool for basic discovery and high-throughput drug screening for G-protein-coupled receptors and ion channels. We optimized and validated this potentiometric probe to assay functional modulators of heterologous expressed GABA

Indexed as

AnimalsDose-Response Relationship, DrugFluorescent DyesGABA AntagonistsGABA ModulatorsHEK293 CellsHumansMembrane PotentialsMiceProtein SubunitsReceptors, GABA-AFluorescent DyesGABA AntagonistsGABA ModulatorsProtein SubunitsReceptors, GABA-A

Identifiers

PMID28428226
PMCPMC5452057
OpenAlexW2606635868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.